Atossa Therapeutics announced that it has entered into a securities purchase agreement with institutional investors for a registered direct offering that is expected to generate approximately $4.5 million in upfront gross proceeds, with the potential for total gross proceeds of up to $16.5 million through the exercise of warrants.
The clinical-stage biopharmaceutical company said the transaction includes the sale of 1,363,638 shares of common stock, or common stock equivalents, together with Series A warrants and short-term Series B warrants to purchase up to an additional 1,363,638 shares each. The warrants will become exercisable six months after issuance.
Series A warrants will remain outstanding for 5.5 years, while the Series B warrants will expire two years after issuance. If all warrants are exercised on a cash basis, Atossa could receive approximately $12 million in additional gross proceeds. However, the company noted there is no assurance that the warrants will be exercised.
The offering is expected to close on or about June 12, 2026, subject to customary closing conditions. Rodman & Renshaw is serving as the exclusive placement agent for the transaction.
Atossa said it intends to use the proceeds to support clinical development of its product candidates, working capital requirements, and general corporate purposes.
Headquartered in Seattle, Atossa Therapeutics is a clinical-stage biotechnology company focused on developing therapies in oncology and other areas of significant unmet medical need. Its lead product candidate, (Z)-endoxifen, is currently being evaluated across multiple clinical settings.
